Biomarkers for early detection of Alzheimer disease

Journal of the American Osteopathic Association

Volumn 110, Issue 9 SUPPL. 8, 2010, Pages

  Barber, Robert C ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; GENETIC MARKER; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROGNOSIS; REVIEW; TIME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CEREBROSPINAL FLUID; GENETIC MARKERS; HUMANS; MAGNETIC RESONANCE IMAGING; PROGNOSIS; TIME FACTORS;

EID: 78651383987     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Alzheimer Association. 2010 Alzheimer disease facts and figures. Alzheimers Dement. 2010;6(2): 158-194. http://www.alzheimersanddementia.com/article/PIIS1552526010000142/fulltext. Accessed August 13, 2010.
2. Allan CL, Sexton CE, Welchew D, Ebmeier KP. Imaging and biomarkers for Alzheimer disease [published online ahead of print January 8, 2010] [review]. Maturitas. 2010;65(2):138-142.
3. Molsa PK, Paljarvi L, Rinne JO, Rinne UK, Sako E. Validity of clinical diagnosis in dementia: a prospective clinicopathological study. J Neurol Neurosurg Psychiatry.1985;48(11):1085-1090. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1028565/. Accessed August 13, 2010.
4. Growdon JH. Biomarkers of Alzheimer disease [review]. Arch Neurol. 1999;56(3):281-283. http://archneur.ama-assn.org/cgi/reprint/56/3/281. Accessed August 13, 2010.
5. Feldman HH, Jacova C, Robillard A, et al. Diag-nosis and treatment of dementia: 2. Diagnosis [review]. CMAJ. 2008;178(7):825-836.
6. Waldemar G, Dubois B, Emre M, et al; EFNS. Recommendations for the diagnosis and management of Alzheimer disease and other disorders associated with dementia: EFNS guideline [review]. Eur J Neurol. 2007;14(1):e1-26.
7. Harvan JR, Cotter V. An evaluation of dementia screening in the primary care setting. J Am Acad Nurse Pract. 2006;18(8):351-360.
8. Boustani M, Callahan CM, Unverzagt FW, et al. Implementing a screening and diagnosis program for dementia in primary care. J Gen Intern Med. 2005;20(7):572-577. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1490164/. Accessed August 13, 2010.
9. Alzheimer's Association. 2008 Alzheimer disease facts and figures. Alzheimers Dement. 2008;4(2): 110-133.
10. Alzheimer's Association. Changing the Trajectory of Alzheimer Disease: A National Imperative. Chicago, IL: Alzheimer's Association; 2010. http://www.alz.org/documents_custom/trajectory.pdf. Accessed August 13, 2010.
11. O'Bryant SE, Hobson V, Hall JR, et al; Texas Alzheimer Research Consortium. Brain-derived neurotrophic factor levels in Alzheimer disease. J Alzheimers Dis. 2009;17(2):337-341. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787708/. Accessed August 13, 2010.
12. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer Disease''. The Ronald and Nancy Reagan Research Institute of the Alzheimer Association and the National Institute on Aging Working Group [published correction appears in Neurobiol Aging. 1998;19(3):285]. Neurobiol Aging. 1998;19(2):109-116.
13. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer disease [published online ahead of print October 10, 2007]. Brain. 2007;130(pt 11):2837-2844. http://brain.oxfordjournals.org/cgi/content/full/130/11/2837?view=long&pmid=17928318. Accessed August 13, 2010.
14. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001;69(13): 1471-1484.
15. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.
16. Engler H, Santillo AF, Wang SX, et al. In vivo amyloid imaging with PET in frontotemporal dementia [published online ahead of print September 11, 2007]. Eur J Nucl Med Mol Imaging. 2008;35(1):100-106.
17. Nordberg A. Amyloid imaging in Alzheimer disease [review]. Curr Opin Neurol. 2007;20(4):398-402.
18. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment [published online ahead of print May 11, 2007]. Neurobiol Aging. 2008;29 (10):1456-1465.
19. Mormino EC, Kluth JT, Madison CM, et al; Alzheimer Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects [published online ahead of print November 28, 2008]. Brain. 2009;132(pt 5):1310-1323. http://brain.oxford-journals.org/cgi/content/full/132/5/1310?view=long&pmid=19042931. Accessed August 13, 2010.
20. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509-1517. http://archneur.ama-assn.org/cgi/content/full/65/11/1509. Accessed August 13, 2010.
21. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer disease [published online ahead of print April 3, 2009]. Proc Natl Acad Sci USA. 2009;106(16):6820-6825. http://www.pnas.org/content/106/16/6820.long. Accessed August 13, 2010.
22. Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer disease. J Neurosci. 2001;21(24):RC189. http://www.jneurosci.org/cgi/content/full/21/24/RC189. Accessed August 13, 2010.
23. Agdeppa ED, Kepe V, Liu J, et al. 2-dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer disease. Mol Imaging Biol. 2003;5(6):404-417.
24. Teipel SJ, Meindl T, Grinberg L, Heinsen H, Hampel H. Novel MRI techniques in the assessment of dementia [review]. Eur J Nucl Med Mol Imaging. 2008;35 suppl 1:S58-S69.
25. Wang PN, Lirng JF, Lin KN, Chang FC, Liu HC. Prediction of Alzheimer disease in mild cognitive impairment: a prospective study in Taiwan. Neurobiol Aging. 2006;27(12):1797-1806.
26. Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52(7):1397-1403. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730146/. Accessed August 14, 2010.
27. Taoka T, Morikawa M, Akashi T, et al. Fractional anisotropy-threshold dependence in tract based diffusion tensor analysis: evaluation of the uncinate fasciculus in Alzheimer disease [published online ahead of print June 18, 2009]. AJNR Am J Neuroradiol. 2009;30(9):1700-1703.
28. Tanzi RE, Kovacs DM, Kim TW, Moir RD, Guenette SY, Wasco W. The gene defects responsible for familial Alzheimer disease [review]. Neurobiol Dis. 1996;3(3):159-168.
29. Blennow K, de Leon MJ, Zetterberg H. Alzheimer disease. Lancet. 2006;368(9533):387-403.
30. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer disease [published online ahead of print September 6, 2009]. Nat Genet. 2009;41(10):1088-1093. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845877/. Accessed August 14, 2010.
31. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E poly-morphism and Alzheimer disease. Lancet. 1993;342(8873):697-699.
32. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90(5):1977-1981. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC46003/. Accessed August 14, 2010.
33. Lambert JC, Heath S, Even G, et al. Genomewide association study identifies variants at CLU and CR1 associated with Alzheimer disease [published online ahead of print September 6, 2009]. Nat Genet. 2009;41(10):1094-1099.
34. Polvikoski T, Sulkava R, Haltia M, et al. Apoli-poprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995;333(19):1242-1247. http://www.nejm.org/doi/full/10.1056/NEJM199511093331902. Accessed August 14, 2010,
35. Wolk DA, Dickerson BC, Weiner M, et al. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer disease [published online ahead of print May 17, 2010]. Proc Natl Acad Sci USA. 2010;107(22):10256-10261.
36. Glodzik L, de Santi S, Tsui WH, et al. Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders [published online ahead of print February 2, 2010]. Neurobiol Aging.
37. Fjell AM, Amlien IK, Westlye LT, et al. CSF biomarker pathology correlates with a medial temporo-parietal network affected by very mild to moderate Alzheimer disease but not a fronto-striatal network affected by healthy aging [published online ahead of print September 30, 2009]. Neuroimage. 2010;49(2):1820-1830.
38. Fjell AM, Walhovd KB, Fennema-Notestine C, et al; the Alzheimer Disease Neuroimaging Initiative. Brain atrophy in healthy aging is related to CSF levels of A{beta}1-42 [published online ahead of print January 4, 2010]. Cereb Cortex.
39. Fjell AM, Walhovd KB, Fennema-Notestine C, et al; the Alzheimer Disease Neuroimaging Initiative. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer disease. J Neurosci. 2010;30(6):2088-2101. http://www.jneurosci.org/cgi/content/full/30/6/2088. Accessed August 14, 2010.
40. Mulder C, Verwey NA, van der Flier WM, et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease [published online ahead of print October 15, 2009]. Clin Chem. 2010;56 (2):248-253.
41. Engelborghs S, Maertens K, Vloeberghs E, et al. Neuropsychological and behavioural correlates of CSF biomarkers in dementia [published online ahead of print January 24, 2006]. Neurochem Int. 2006;48(4):286-295.
42. De Meyer G, Shapiro F, Vanderstichele H, et al; for the Alzheimer Disease Neuroimaging Initiative. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67(8):949-956.
43. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phos-phorylated tau protein as biological markers of Alzheimer disease [published online ahead of print October 22, 2009]. Exp Gerontol. 2010;45(1):30-40.
44. Bibl M, Mollenhauer B, Lewczuk P, et al. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias [published online ahead of print March 6, 2007]. Mol Psychiatry. 2007;12(7):671-680.
45. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults [published online ahead of print January 8, 2007]. Arch Neurol. 2007;64(3):343-349.
46. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65(2):176-183.
47. Rosso SM, van Herpen E, Pijnenburg YA, et al. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. Arch Neurol. 2003;60(9):1209-1213. http://archneur.ama-assn.org/cgi/content/full/60/9/1209. Accessed August 14, 2010.
48. Hampel H, Teipel SJ. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord. 2004;17(4):350-354.
49. Buerger K, Zinkowski R, Teipel SJ, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol. 2002;59(8): 1267-1272. http://archneur.ama-assn.org/cgi/content/full/59/8/1267. Accessed August 14, 2010.
50. Brunnstrom H, Rawshani N, Zetterberg H, et al. Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimers Dement. 2010;6(2):104-109.
51. Schneider P, Hampel H, Buerger K. Biological marker candidates of Alzheimer disease in blood, plasma, and serum. CNS Neurosci Ther. 2009;15(4): 358-374.
52. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins [published online ahead of print October 14, 2007]. Nat Med. 2007;13(11):1359-1362.
53. O'Bryant S, Xiao G, Barber R, et al. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol. In press.